Global Oncology Academy

Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
- David Feller-Kopman, MD
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Project Oncology®
AAT C-Terminal Peptides Show Independent Prognostic Value in Early-Stage NSCLC
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival
Project Oncology®
Impacts of Multidisciplinary Tumor Boards and Surgery Integration on NSCLC Survival

Medical News

Medical News
Dual-Energy CT Enhances Image Quality for Liver Metastases Without Increasing Detection
10/24/2025
Read more
Medical News
POWER4 Data: Anemia Flags Risk but Isn’t a Confirmed Driver of Recurrence
10/23/2025
Read more
Medical News
Thymic Health Identified as Key Predictor of Immunotherapy Outcomes
10/21/2025
Read more
Medical News
Loneliness May Be a Hidden Risk Factor in Cancer Survival, New Review Finds
10/16/2025
Read more

See more news

CME/CE

Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
MinuteCE®
Emerging Clinical Evidence for B7-H3–Directed ADCs in ES-SCLC From WCLC 2025
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
CME/CE
Global Perspectives on Perioperative Immunotherapy in LA HNSCC
0.25 credits
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
- Christophe Le Tourneau, MD, PhD
0.25 credits
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
CME/CE
Advanced Therapeutic Strategies and Resistance Mechanisms in CLL
0.25 credits
- Shankara Paneesha, MD FRCP FRCPath
0.25 credits
HER2-Driven Strategies in Metastatic NSCLC
HER2-Driven Strategies in Metastatic NSCLC
MinuteCE®
HER2-Driven Strategies in Metastatic NSCLC
1.25 program credits
- Stephen Liu, MD
- Joshua K. Sabari, MD
- Susan Scott, MD
1.25 program credits

Clinical Practice

Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- Hallie Blevins, PhD.
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Paul L Swiecicki, MD

Programs

Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
Project Oncology®
Evaluating Patient and Clinician-Reported Responses to Axatilimab in cGVHD
- Brian P. McDonough, MD, FAAFP
- Christopher Graham, MD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Project Oncology®
Crizanlizumab’s Role in Reducing Vaso-Occlusive Crises and Opioid Use in SCD
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
MinuteCE®
Rethinking the Therapeutic Targeting of B7-H3 in ES-SCLC 
0.50 program credits
- Lauren A. Byers, MD
0.50 program credits
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
MinuteCE®
Translating Clinical Data Into Multidisciplinary Practice for ES-SCLC 
0.50 program credits
- Luis Paz-Ares, MD, PhD
- Lauren A. Byers, MD
0.50 program credits